Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months

    Hepatitis C medications approved in March this year have already topped the list of Australia's most expensive drugs, costing the taxpayer $1 billion. The latest figures have outlined 10 most prescribed and most expensive drugs on the Pharmaceutical Benefits Scheme (PBS) in the past year.

    05 December 2016 | ABC Online
  • New WHO report shows strategic purchasing of medicines can improve access in the European Region

    A new WHO report provides insight into how countries in the WHO European Region can improve access and reduce medicine prices through strategic and well-planned procurement processes. The report examines the effect of different public procurement practices on supply security and prices for pharmaceuticals. It also addresses collaboration within and across countries to improve availability of affordable medicines for patients in the Region.

    02 December 2016 | World Health Organization
  • DAA treatment restricted for Canadian hepatitis C patients

    Patients infected by hepatitis C virus (HCV) in Canada have limited access to direct-acting antiviral (DAA) agents, according to a new study. For example, 85% to 92% of the provinces and territories in Canada restrict access to these medications to persons with moderate fibrosis.

    29 November 2016 | Medical Economics
  • Where hepatitis C rates are seven times the US average — and a cure is kept out of reach

    With the opioid epidemic steamrolling through Appalachia, the new face of hepatitis C is increasingly young, white, and rural. In Kentucky, a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach.

    14 November 2016 | STAT
  • These researchers think they have a solution to the global crisis in drug prices

    To avoid the cost and uncertainty of challenging behemoth drug companies in the American market, Trek plans to focus on middle-income countries where new hepatitis C drugs have been slow to roll out, such as nations in eastern and central Europe. If they are successful at finding a new balancing point of profit and access -- a true "if" -- they hope their example could inspire companies working on other diseases to experiment with similar pricing models.

    08 November 2016 | Washington Post
  • Buyers clubs for cheaper drugs help fight hepatitis and HIV

    Frustrated by the high price of antiviral drugs, thousands of patients from London to Moscow to Sydney are turning to a new wave of online "buyers clubs" to get cheap generic medicines to cure hepatitis C and protect against HIV infection.

    07 November 2016 | Reuters
  • The Cost Of A Cure: Revisiting Medicare Part D And Hepatitis C Drugs

    Preliminary estimates, based on data obtained from CMS by the Associated Press, suggest that 2015 spending on the new hepatitis C drugs was $9.2 billion or roughly double the 2014 levels. This level of spending projects to about 100,000 new individual users, allowing for some duplication of people who continued the treatment they started in 2014.

    04 November 2016 | Health Affairs (blog)
  • Gilead sales of Hepatitis C drugs slump

    Gilead Sciences Inc. on Tuesday said sales of hepatitis C drugs Harvoni and Sovaldi missed expectations and slumped in the third-quarter, as the biopharmaceutical company faces challenges from rival drugs and pricing pressures.

    02 November 2016 | MarketWatch
  • Over 1 million treated with highly effective hepatitis C medicines

    Over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.

    27 October 2016 | World Health Organization
  • A promising Hep C program seems to be working — and it could be a model for other countries

    Georgia, a country nestled against the Black Sea between Turkey and Russia with a population of 3.7 million, has since taken on a public health effort to help reduce its prevalence of hepatitis C (HCV for short) by 90% by 2020.

    24 October 2016 | Business Insider
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.